Research Analysts’ Updated EPS Estimates for September, 13th (AAPL, ADMS, ALXN, BHVN, BIIB, CBS, CNC, COHR, CP, DLB)

Research Analysts’ updated eps estimates for Wednesday, September 13th:

Apple (NASDAQ:AAPL) had its buy rating reiterated by analysts at Bank of America Corporation. Bank of America Corporation currently has a $180.00 target price on the stock.

Adamas Pharmaceuticals (NASDAQ:ADMS) had its buy rating reiterated by analysts at Mizuho. Mizuho currently has a $26.00 target price on the stock.

Alexion Pharmaceuticals (NASDAQ:ALXN) had its outperform rating reissued by analysts at Leerink Swann. The firm currently has a $182.00 price target on the stock, up from their previous price target of $170.00.

Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $43.00 price target on the stock, up from their previous price target of $30.00.

Biogen (NASDAQ:BIIB) had its neutral rating reissued by analysts at Mizuho. They currently have a $319.00 price target on the stock, up from their previous price target of $274.00.

CBS Corporation (NYSE:CBS) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $80.00 price target on the stock.

Centene Corporation (NYSE:CNC) had its market perform rating reissued by analysts at Leerink Swann. They currently have a $90.00 price target on the stock, up from their previous price target of $78.00.

Centene Corporation (NYSE:CNC) had its outperform rating reaffirmed by analysts at Cowen and Company. The firm currently has a $105.00 price target on the stock, up from their previous price target of $77.00.

Coherent (NASDAQ:COHR) had its buy rating reissued by analysts at Stifel Nicolaus. They currently have a $290.00 price target on the stock.

Canadian Pacific Railway Limited (NYSE:CP) (TSE:CP) had its sector perform rating reiterated by analysts at National Bank Financial. The firm currently has a $207.00 price target on the stock, down from their previous price target of $219.00.

Dolby Laboratories (NYSE:DLB) had its neutral rating reissued by analysts at Piper Jaffray Companies. They currently have a $52.00 target price on the stock, up from their previous target price of $49.00.

DIALOG SEMICONDUCT GBP0.10 (NASDAQ:DLGNF) had its buy rating reaffirmed by analysts at J P Morgan Chase & Co.

The Finish Line (NASDAQ:FINL) was upgraded by analysts at Susquehanna Bancshares Inc from a neutral rating to a positive rating. Susquehanna Bancshares Inc currently has $12.00 target price on the stock, up from their previous target price of $9.00.

Incyte Corporation (NASDAQ:INCY) had its buy rating reissued by analysts at Argus. They currently have a $150.00 target price on the stock.

Nordstrom (NYSE:JWN) had its outperform rating reissued by analysts at Cowen and Company. The firm currently has a $53.00 target price on the stock, up from their previous target price of $49.00.

CarMax (NYSE:KMX) had its outperform rating reissued by analysts at Wedbush. They currently have a $68.50 target price on the stock, down from their previous target price of $77.00.

L Brands (NYSE:LB) had its market perform rating reaffirmed by analysts at Wells Fargo & Company. They currently have a $40.00 target price on the stock, down from their previous target price of $45.00.

Lydall (NYSE:LDL) was upgraded by analysts at Sidoti from a neutral rating to a buy rating.

Laboratory Corporation of America Holdings (NYSE:LH) had its hold rating reaffirmed by analysts at Jefferies Group LLC. They currently have a $170.00 price target on the stock, up from their previous price target of $157.00.

McDonald’s Corporation (NYSE:MCD) had its buy rating reiterated by analysts at Mizuho. The firm currently has a $173.00 target price on the stock, up from their previous target price of $170.00.

Nike (NYSE:NKE) had its buy rating reaffirmed by analysts at Deutsche Bank AG. The firm currently has a $61.00 price target on the stock, down from their previous price target of $69.00.

Progress Software Corporation (NASDAQ:PRGS) had its buy rating reaffirmed by analysts at Benchmark Co.. They currently have a $42.00 target price on the stock, up from their previous target price of $34.00.

Reata Pharmaceuticals (NASDAQ:RETA) had its outperform rating reissued by analysts at Leerink Swann. Leerink Swann currently has a $43.00 target price on the stock.

Sage Therapeutics (NASDAQ:SAGE) had its hold rating reaffirmed by analysts at Chardan Capital.

Scana Corporation (NYSE:SCG) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “SCANA is well positioned in a positive regulatory environment, having a low risk business with outstanding customer growth and operational efficiency. The company also has an attractive and consistent dividend payout. However, SCANA Corp.’s price chart shows that it has lagged the industry over the last three months. Westinghouse Electric Co., which is presently constructing a nuclear plant for SCANA, has filed for bankruptcy. Although Westinghouse is anticipated to finish the construction of nuclear reactors, SCANA might face delays and a significant increase in cost. Thus, the future earnings growth of the company looks uncertain.”

Synergy Pharmaceuticals (NASDAQ:SGYP) had its sell rating reiterated by analysts at Citigroup Inc.. The firm currently has a $2.50 target price on the stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its buy rating reaffirmed by analysts at Gabelli.

Tesla (NASDAQ:TSLA) had its underweight rating reiterated by analysts at Barclays PLC. The firm currently has a $210.00 price target on the stock, up from their previous price target of $165.00.

TherapeuticsMD (NASDAQ:TXMD) had its buy rating reaffirmed by analysts at Deutsche Bank AG. They currently have a $10.00 target price on the stock.

Wells Fargo & (NYSE:WFC) had its neutral rating reiterated by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $50.00 target price on the stock, down from their previous target price of $52.00.

Willbros Group (NYSE:WG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $3.00 target price on the stock. According to Zacks, “Willbros Group, Inc. is an independent contractor serving the oil, gas and power industries, providing construction, engineering and specialty services to industry and government entities worldwide. They place particular emphasis on projects in developing countries where they believe their experience gives them a competitive advantage. “

Wintrust Financial Corporation (NASDAQ:WTFC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $79.00 target price on the stock. According to Zacks, “Wintrust Financial Corporation is a bank holding company which provides banking services, trust and investment services, commercial insurance premium financing, short-term accounts receivable financing, and certain administrative services. They provide community-oriented, personal and commercial banking services through their subsidiaries, Lake Forest Bank & Trust Company, Hinsdale Bank & Trust Company, North Shore Community Bank & Trust Company, Libertyville Bank & Trust Company, Barrington Bank & Trust Company, Crystal Lake Bank & Trust Company, and Northbrook Bank & Trust Company. “

Yum China Holdings (NASDAQ:YUMC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Yum China Holdings, Inc. is a licensee of Yum! Brands primarily in mainland China. The company have rights to KFC, China’s quick-service restaurant concept, Pizza Hut, casual dining restaurant brand and Taco Bell. Yum China Holdings, Inc. is based in Shanghai, China. “

Yanzhou Coal Mining Co (NASDAQ:YZCAY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $11.00 target price on the stock. According to Zacks, “Yanzhou Coal Mining Company Limited is engaged in the underground mining of prime quality, low-sulfur coal from its mines in Shandong Province, China and is one of China’s largest coal producers and coal exporters. Based on coal output per production employee, the company is one of the most efficient underground coal mining enterprises in China.(Press Release) “

Zafgen (NASDAQ:ZFGN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3.75 price target on the stock. According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “

Receive News & Ratings for Apple Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply